645 results on '"Caviglia, Gian Paolo"'
Search Results
2. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
3. A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis
4. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
5. A nutrigenetic precision approach for the management of Non-alcoholic Fatty Liver Disease
6. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis
7. FRI-392-YI Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV monoinfection, that parallels HDV replicative and cytolytic activity
8. WED-243-YI Irisin level as a potential biomarker for hepatic steatosis improvement after a 6-month lifestyle intervention in patients with metabolic dysfunction-associated steatotic liver disease
9. WED-233-YI The single nucleotide polymorphism rs780094 C>T in the glucokinase regulator gene (GCKR) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disease
10. SAT-031-YI Evolution of pre liver transplant cardiovascular risk factors and cardiac work-up: impact on post-transplant events
11. FRI-243 Echocardiography-based markers of subclinical cardiac dysfunction in patients with MASLD and preserved ejection fraction: prospective data from the Turin cohort
12. THU-486-YI A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events
13. FRI-251-YI Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and/or type 2 diabetes-mellitus
14. SAT-015-YI Screening for asymptomatic coronary artery disease in liver transplant recipients: is it time to replace stress echocardiography with coronary CT angiography in selected patients?
15. FRI-314 Plasminogen activator inhibitor-1 (PAI-1) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
16. WED-293 Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease
17. FRI-405 Heterogeneity in the diagnostic performances of HDV-RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study
18. FRI-230-YI Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and nonhepatological healthcare pathway model: preliminary results from a prospective cohort of a tertiary center
19. OS-094 Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBV-DNA in the setting of a limited or even absent HBV reservoir
20. THU-517 Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: experience from two international centres
21. FRI-479-YI The role of OSM/OSMRβ axis in shaping the immunemicroenvironment favouring MASLD-related HCC immune evasion
22. Extracellular Vesicle-Enclosed Oxidative Stress- and Inflammation-Related microRNAs as Potential Biomarkers of Vitamin D Responsivity: A Pilot Study on Inflammatory Bowel Disease Patients with or without COVID-19.
23. MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment.
24. Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study
25. Helicobacter pylori in Inflammatory Bowel Diseases: Active Protagonist or Innocent Bystander?
26. Cross Talk between Gut Microbiota and Immune System: From Pathophysiology to Potential Therapeutic Interventions in Inflammatory Bowel Disease
27. Reply to: “The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis”
28. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease
29. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants
30. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
31. A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.
32. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection
33. Correlation between Polymorphisms of Vitamin D Metabolism Genes and Perianal Disease in Crohn’s Disease
34. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
35. The Histology-Driven Differential Diagnosis in Bowel Inflammatory Conditions Is Not All That Obvious: Evidence from a Survey Based on Digital Slides
36. High Mobility Group Box-1 as a Candidate Biomarker of Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma
37. Faecal miRNA profiles associated with age, sex, BMI, and lifestyle habits in healthy individuals
38. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study
39. Risk of drug interactions and prescription appropriateness in elderly patients
40. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis
41. Induced pluripotent stem cells from spermatogonial stem cells
42. Contributors
43. Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
44. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection
45. Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
46. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
47. Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease
48. Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
49. De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
50. Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.